Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218823 · ClinicalTrials.gov registry record · Phase 4
Tobacco Treatment Comparison for Cancer Care
A Phase 4 study of Cancer and Smoking Cessation, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06218823: Completed Phase 4 study of Cancer and Smoking Cessation, sponsored by University of Wisconsin, Madison.
NCT06218823 is a Phase 4 study of Cancer and Smoking Cessation that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 52 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06218823, a Phase 4 study of Cancer and Smoking Cessation, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.
Primary Outcome
This measure is confirmed by expired carbon monoxide and/or a cotinine urine or saliva sample test.
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Transdermal Nicotine Patch
- BEHAVIORAL Standard Telephone Counseling
- BEHAVIORAL Cancer-Targeted Telephone Counseling
- OTHER Mailed Information about Standard Care Resources
Study Locations (1)
Wisconsin
- UW Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 4 |
What the finished NCT06218823 record still lists
NCT06218823 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Varenicline is the first listed.
NCT06218823 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06218823 about?
NCT06218823 is a clinical study titled "Tobacco Treatment Comparison for Cancer Care". This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline...
What is the current status of trial NCT06218823?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2024-03-01. Estimated completion is 2025-08-04.
What conditions does trial NCT06218823 study?
This clinical trial studies the following conditions: Cancer, Smoking Cessation.
What interventions are being tested in trial NCT06218823?
The interventions under investigation include: Varenicline (DRUG), Transdermal Nicotine Patch (DRUG), Standard Telephone Counseling (BEHAVIORAL), Cancer-Targeted Telephone Counseling (BEHAVIORAL), Mailed Information about Standard Care Resources (OTHER).
Who is sponsoring clinical trial NCT06218823?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218823 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06218823's enrollment target sits among peer trials
52 418th of 615 higher than 197 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
COMPLETED · Phase 4
-
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI